LAG3 and melanoma: Importantly, the combination of anti-LAG-3 (BMS-986016) and anti-PD-1 (nivolumab) antibodies has been shown to be effective in melanoma patients resistant to anti-PD-1/PD-L1 therapy [63], and is currently being tested in other tumor types (NCT04082364, NCT01968109).